NCT07589296 Robot-Assisted Gait Training vs NMES in Parkinson's Disease
| NCT ID | NCT07589296 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kanuni Sultan Suleyman Training and Research Hospital |
| Condition | Parkinson Disease (PD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-04-15 |
| Primary Completion | 2026-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-04-15 with a primary completion date of 2026-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, randomized, assessor-blinded clinical trial aims to compare the effects of robot-assisted gait training and quadriceps neuromuscular electrical stimulation (NMES) when added to a standard exercise rehabilitation program in patients with Parkinson disease. Participants will be randomly assigned to two parallel groups. Both groups will receive a standard rehabilitation program, while one group will additionally undergo robot-assisted gait training and the other group will receive quadriceps NMES. The interventions will be administered five days per week for six weeks. Clinical outcomes, including balance, functional mobility, gait performance, and disease severity, will be evaluated at baseline, post-treatment, and follow-up (week 14). In addition, ultrasound-based assessments of quadriceps muscle thickness and cross-sectional area will be performed to investigate muscle adaptations. The results of this study are expected to provide comparative evidence regarding the effectiveness of these two rehabilitation approaches and contribute to optimizing rehabilitation strategies in Parkinson disease.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Parkinson's disease according to established clinical criteria * Age between 40 and 80 years * Hoehn and Yahr stage II-III * Ability to walk independently with or without assistive devices * Stable medical treatment for at least 4 weeks prior to study enrollment * Ability to understand and follow instructions * Willingness to participate and provide written informed consent Exclusion Criteria: * Severe cognitive impairment or inability to follow instructions * Hoehn and Yahr stage IV-V Parkinson's disease * Severe musculoskeletal disorders affecting gait (e.g., advanced osteoarthritis, recent fracture) * History of lower extremity surgery within the last 6 months * Severe cardiovascular or respiratory disease limiting exercise participation * Presence of other neurological disorders affecting mobility (e.g., stroke, multiple sclerosis) * Contraindications to electrical stimulation (e.g., pacemaker, implanted electronic devices) * Skin lesions or infections at electrode placement sites * Participation in another structured rehabilitation program within the last 3 months
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07589296 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Parkinson Disease (PD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07589296 currently recruiting?
Yes, NCT07589296 is actively recruiting participants. Contact the research team at dilekunoguzhan@gmail.com for enrollment information.
Where is the NCT07589296 trial being conducted?
This trial is being conducted at Küçükçekmece, Turkey (Türkiye).
Who is sponsoring the NCT07589296 clinical trial?
NCT07589296 is sponsored by Kanuni Sultan Suleyman Training and Research Hospital. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.